Results 61 to 70 of about 4,202 (211)

Daratumumab Treatment for Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP): A Case Report

open access: yesAnnals of Clinical and Translational Neurology, Volume 13, Issue 3, Page 622-626, March 2026.
ABSTRACT Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an immune‐mediated neuropathy featuring progressive weakness, sensory deficits, and areflexia. While corticosteroids, intravenous immunoglobulin, and plasmapheresis are effective first‐line immunotherapies, a subset of patients remains treatment‐refractory.
Xueyu Zhang   +8 more
wiley   +1 more source

Aberrant tRNA processing causes an autoinflammatory syndrome responsive to TNF inhibitors [PDF]

open access: yes, 2018
OBJECTIVES: To characterise the clinical features, immune manifestations and molecular mechanisms in a recently described autoinflammatory disease caused by mutations in TRNT1, a tRNA processing enzyme, and to explore the use of cytokine inhibitors in ...
et al   +3 more
core   +1 more source

Clonal haematopoiesis in chronic lymphocytic leukaemia: Biology, inflammaging and clinical implications in the era of targeted therapy

open access: yesClinical and Translational Medicine, Volume 16, Issue 3, March 2026.
In an ageing and inflamed haematopoietic ecosystem, clonal haematopoiesis and chronic lymphocytic leukaemia may originate from shared or parallel stem cell clones. This interaction modulates the effects of targeted therapies and contributes to cytopenias, cardiovascular toxicity, therapy‐related myeloid neoplasms and Richter transformation.
Enrica Antonia Martino   +12 more
wiley   +1 more source

Pragmatic treatment of patients with Systemic Lupus Erythematosus with rituximab: Long-term effects on serum immunoglobulins [PDF]

open access: yes, 2016
OBJECTIVE: B cell depletion therapy based on rituximab is a therapeutic option for refractory disease in patients with Systemic Lupus Erythematosus (SLE).
Cambridge, G   +4 more
core  

Primary hypogammaglobulinaemia and arthritis. [PDF]

open access: yesBMJ, 1987
Arthritis may be the first clinical manifestation of primary hypogammaglobulinaemia. In 16 years of 281 patients who had immunodeficiency, 30 had arthritis at presentation. It was more common in Bruton's disease (15 (22%) of 69 patients) than in other forms of immunodeficiency (15 (7%) of 212 patients).
T T, Hansel, M R, Haeney, R A, Thompson
openaire   +2 more sources

Adverse events associated with use of immunoglobulin in pediatric patients reported to the US Food and Drug Administration Adverse Event Reporting System, 2001–2023

open access: yesPediatric Allergy and Immunology, Volume 37, Issue 3, March 2026.
Abstract Background Immunoglobulin products are widely used for the treatment of immunodeficiency and autoimmune disorders. Although clinical trials have demonstrated their efficacy and tolerability, data describing their postmarketing safety profile in pediatric populations remain limited, particularly regarding rare and serious adverse events.
Shaokui Wei   +4 more
wiley   +1 more source

Handbook of clinical immunology [PDF]

open access: yes, 2008
ИММУНОЛОГИЯУЧЕБНИКИIMMUNOLOGYУчебник по курсу "Иммунология" написан для иностранных студентов.
Vykhrystenka, L. R., Yanchanka, U. V.
core  

Measurement and interpretation of Salmonella typhi Vi IgG antibodies for the assessment of adaptive immunity [PDF]

open access: yes, 2018
Response to polysaccharide vaccination can be an invaluable tool for assessing functionality of the adaptive immune system. Measurement of antibodies raised in response to Pneumovax®23 is the current gold standard test, but there are significant ...
Bradley, Caroline   +5 more
core   +2 more sources

An unusual case of multiple myeloma [PDF]

open access: yes, 2013
The case concerns the unusual presentation of a non-secretory multiple myeloma with diarrhoea secondary to large bowel infiltration. In December 2009, a 74-year-old lady presented to hospital and complained of a two year history of intermittent ...
Delicata, Julian, Farrugia, Daniel
core  

The Direction of Modern Therapies in Waldenström Macroglobulinaemia

open access: yesJournal of Cellular and Molecular Medicine, Volume 29, Issue 24, December 2025.
ABSTRACT Waldenström macroglobulinaemia (WM) is a rare lymphoplasmacytic disease that is hallmarked by B‐cell infiltration of the bone marrow, an overexpression of IgM class antibodies and an activating mutation of MYD88 (L265P). The therapeutic options for WM patients include a combination of Rituximab (anti‐CD20 monoclonal antibody) and chemotherapy,
Stephen Blackmore   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy